Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology
Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
- Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
- Screening was performed on stabilized whole blood samples from 1,384 individuals meeting National Lung Screening Trial (NLST) lung cancer eligibility criteria (age 55-74, pack-years ≥30) by leveraging ultra-deep small RNA sequencing.
- The miLung small RNA blood test is noninvasive and identifies specific small RNAs, molecular biomarkers associated with lung cancer in whole blood samples that can be drawn at the point of care.
- “Early cancer detection remains the most effective strategy to reduce mortality associated with lung cancer,” commented Jochen Kohlhaas, Founder and Chief Executive Officer of Hummingbird Diagnostics.